The European Union’s proposed Biotech Act is advancing as a strategy to restore global competitiveness, with stakeholders emphasizing two practical goals: harmonizing pathways to market and strengthening manufacturing investment. Speaking at BIO-Europe Spring in Lisbon, EuropaBio Director General Claire Skentelbery framed the Act as a “generational opportunity” for European biotech. Alliance for Regenerative Medicine representatives highlighted how trial fragmentation and overlapping national requirements have discouraged sponsors from choosing Europe. The Act is also aimed at reducing risk aversion and improving venture and scaling conditions for small and mid-size companies. For biotech executives planning Europe strategy, the immediate watch-items are regulatory simplification across countries and policies that speed clinical development decision cycles without creating new compliance bottlenecks.